A Rare Case of Gemcitabine-Induced Pulmonary Hypertension.

Autor:	Shen J; Division of Hematology-Oncology, Department of Medicine, Northwell Health, Manhasset, NY, USA.; Northwell Health Cancer Institute, Monter Cancer Center, Lake Success, NY, USA., Chung SY; Division of Hematology-Oncology, Department of Medicine, Northwell Health, Manhasset, NY, USA.; Northwell Health Cancer Institute, Monter Cancer Center, Lake Success, NY, USA., Azimi-Nekoo E; Division of Hematology-Oncology, Department of Medicine, Northwell Health, Manhasset, NY, USA.; Northwell Health Cancer Institute, Monter Cancer Center, Lake Success, NY, USA., Jose J; Northwell Health Cancer Institute, Monter Cancer Center, Lake Success, NY, USA., Saif MW; Division of Hematology-Oncology, Department of Medicine, Northwell Health, Manhasset, NY, USA.; Northwell Health Cancer Institute, Monter Cancer Center, Lake Success, NY, USA.; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Jazyk:	angličtina
Zdroj:	Pulmonary research and respiratory medicine : open journal [Pulm Res Respir Med] 2019; Vol. 5 (1), pp. 1-3. Date of Electronic Publication: 2019 Dec 20.
DOI:	10.17140/PRRMOJ-5-139
Abstrakt:	Context: Gemcitabine is the backbone of systemic treatment of locally advanced and metastatic intrahepatic cholangiocarcinoma. In recent literature, gemcitabine has been linked to various pulmonary side effects. Case Report: We report a case of an 82-year-old male who developed acute pulmonary hypertension after receiving one cycle of gemcitabine for metastatic cholangiocarcinoma. His symptoms began with fatigue associated with shortness of breath and cough that worsened despite dose reduction. He developed new onset bilateral pulmonary effusions and an echocardiogram revealed findings consistent with pulmonary hypertension. A computed tomography (CT) angiogram was negative for pulmonary thromboembolism. Although he was promptly treated with diuretics and steroids, the patient could not tolerate any further therapy. Conclusion: Gemcitabine-induced pulmonary hypertension is rare and can be challenging to diagnose, as it remains a diagnosis of exclusion. However, physicians should be vigilant of new pulmonary symptoms, as delayed treatment can cause significant patient morbidity and mortality. Competing Interests: CONFLICT OF INTEREST The authors declare that they have no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu